CURRICULUM VITAE. Rocco Giovanni Piazza PERSONAL DATA:



Similar documents
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

CML Drugs and their Availability in the UK. Jane Apperley

The EGFR mutation and precision therapy for lung cancer

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

NGS e malattie mieloproliferative

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

CHRONIC MYELOGENOUS LEUKEMIA

Update in Hematology Oncology Targeted Therapies. Mark Holguin

nilotinib 150mg hard capsules (Tasigna ) SMC No. (709/11) Novartis Pharmaceuticals UK Ltd

La Targeted Therapy e l appropriatezza terapeutica

The CML Guide Information for Patients and Caregivers

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani

Case 2:08-cv ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Analysis One Code Desc. Transaction Amount. Fiscal Period

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

The CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017

A disease of populations of cells that live, divide, invade and spread without regard to normal limits

Molecular markers and clinical trial design parallels between oncology and rare diseases?

New York Presbyterian Hospital 7/2001-6/2003. Montefiore Medical Center 7/1999-6/2001 Resident, Internal Medicine

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

Answering your questions on Chronic Myeloid Leukaemia (CML)

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology

targeted therapy a guide for the patient

Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

A Time Line Of Chronic Myeloid Leukemia

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

Cytogenetic Profile of Variant Philadelphia Translocations in Chronic Myeloid Leukemia

The following information is only meant for people who have been diagnosed with advanced non-small cell

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

E UROPEAN CURRICULUM VITAE FORMAT

Targeted Therapies in Lung Cancer

Hematologic Malignancies

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Understanding series. new. directions LungCancerAlliance.org. A guide for the patient

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Thoracic Oncology Unit

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

The Treatment of Leukemia

Vincenzo Lionetti, M.D., Ph.D.

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Cytogenetics for the Rest of Us: A Primer

Targeted Therapy What the Surgeon Needs to Know


Cure versus control: Which is the best strategy?

CURRICULUM VITAE. Name: Florencia Licastro Job Title: Director, Training and Development. Summary of experience

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

For years, drug developers have used histology as the

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Cancer: DNA Synthesis, Mitosis, and Meiosis

Ashley Institute of Training Schedule of VET Tuition Fees 2015

Amel Abd Allah Hashim Ahmed

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

CURRICULUM VITAE Rosella Visintin. Assistant professor of SEMM (European School of Molecular Medicine). IFOM-IEO Campus Milan - Italy

Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies

How To Understand The Effects Of A Drug On Your Health

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Genes and Cancer. What are genes? Dominant vs. recessive genes

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

The Past, Present & Future of Cancer Immunotherapy:

CENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY Small Commercial Service (SCS-1) GSR

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science

Corporate Medical Policy

ACCESS Nursing Programs Session 1 Center Valley Campus Only 8 Weeks Academic Calendar 8 Weeks

ACCESS Nursing Programs Session 1 Center Valley Campus Only 8 Weeks Academic Calendar 8 Weeks

Recommendations for the Management of BCR-ABL-positive Chronic Myeloid Leukaemia. British Committee for Standards in Haematology.

Recent Review Papers on Simian-Virus (SV-40), Asbestos and Mesothelioma. Bibliography

Daiichi Sankyo to Acquire Ambit Biosciences

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide

Treating Minimal Residual Disease in Acute Leukemias: How low should you go?

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Navigating GIST. The Life Raft Group June 12, 2008

Transcription:

CURRICULUM VITAE Rocco Giovanni Piazza PERSONAL DATA: Date and place of birth: 26 th July 1974, Reggio Calabria (Italy). Citizenship: Italian Address: Via Carducci 8, 20035 Lissone (MB) - Italy Phone +39 340 6132493. E-mail: rocco.piazza@unimib.it EDUCATION: - In 1998: M.D., University of Pavia (110/110 cum laude). - In 1999: admission at the Italian Ph.D. School for Advanced Studies (SAFI). - In 2002: PhD (Biochemistry) at the Department of Biochemistry, University of Pavia. - In 2006: Post graduate education in Haematology at the S. Gerardo Hospital of Monza. - Starting from 2009, researcher (MED/15 - Haematology) at the University of Milano- Bicocca - Known languages: Italian, English, and French (scholastic level). WORK EXPERIENCE: - 1999 2002: PhD in Biochemistry, Department of Biochemistry, University of Pavia. - 2002 2003: PostDoc in Molecular Biology, Division of Experimental Oncology, Oncogenic Fusion Proteins Unit, Istituto Nazionale Tumori, Milano Italy. - 2003 2006 Clinical Haematology Fellow, Department of Haematology, San Gerardo Hospital, Monza Italy. - 2006 2008 PostDoc - Oncohaematology, Department of Clinical Medicine, University of Milano-Bicocca, Milano Italy. - 2008 2011 Researcher in Haematology, Department of Clinical Medicine, University of Milano-Bicocca, Milano Italy.

PRESENT RESEARCH AREA: - High-throughput second-generation sequencing of cancer genomes. - Molecular mechanisms of drug resistance. - Genetic and epigenetic regulation of gene expression in normal and neoplastic cells. - Functional inhibition of oncogenic fusion proteins with tyrosine kinase activity using tyrosine-kinase inhibitors.

AWARDS AND HONORS: - 1992, Italian Chemistry Games: first place at regional level, third place at national level. - 1993: School of Medicine (University of Pavia): ranked first at the admission test (9.75/10). - 1998: M.D.: 110/110 cum laude. - 1999: SAFI prize with the thesis: Immunology and mathematics. - 2000: SAFI prize with the thesis: Virtual ants and swarm intelligence. - 2001: SAFI prize with the thesis: Neural networks and DNA microchips. - 2002: PhD in Biochemistry, Department of Biochemistry, University of Pavia. - 2005: Post graduate education in Haematology: 70/70 cum laude. - 2008: American Association for Cancer Research - Pezcoller Foundation Scholar-in- Training Award for the AACR Annual Meeting 2008 with the abstract: Reversal of glucocorticoid resistance in human lymphoid malignancies with histone deacetylase inhibitors. CLINICAL TRIALS: - Investigator in Clinical Trial 3160A4-200-WW (NCT00261846): Open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). - Investigator in Clinical Trial 3160A4-3000-WW (NCT00574873): Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML. - Investigator in Clinical Trial A8081013 (NCT01121588): An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK). - Investigator in Clinical Trial AP24534 (NCT01207440): PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL). - Investigator in Clinical Trial CA180-056 (NCT00481247): An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL ) vs. Standard Dose Imatinib (400

mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia. - Investigator in Clinical Trial CA180-034 (NCT00123474): A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec). - Investigator in Clinical Trial CINC424A2352 (NCT00934544): A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis. - Investigator in Clinical Trial EWALL-PH-01: Dasatinib (Sprycel ) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL. - Investigator in Clinical Trial ISAV STUDY - Imatinib Suspension and Validation. - Investigator in Clinical Trial ILTE - Imatinib Long Term side-effects study. - Investigator in Clinical Trial (NCT01244750) Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY). - Investigator in Clinical Trial The quality of life in chronic myeloid leukemia patients treated with Imatinib (QUALIMA).

SELECTED PUBLICATIONS: - Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, Francia di Celle P, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NCP, Gambacorti-Passerini C. Nat Genet. 2012 Dec 16;45(1):18-24. - Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Am J Hematol. 2012 Sep 26. doi: 10.1002/ajh.23338. - Piazza R, Pirola A, Spinelli R, Valletta S, Redaelli S, Magistroni V, Gambacorti-Passerini C. Nucleic Acids Res. 2012 Sep 1;40(16):e123. Epub 2012 May 8. - Gambacorti-Passerini C, Piazza R. Am J Hematol. 2011 Jul;86(7):531-2. doi: 10.1002/ajh.22084. - Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C. PLoS One. 2011;6(11):e28162. - Bachmann PS*, Piazza RG*, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Göttgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB, (*Joint First Authors), Blood. 2010 Oct 21;116(16):3013-22. - Marega M*, Piazza RG*, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C, (*Joint First Authors), Leukemia. 2010 Aug;24(8):1445-9. - Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti- Passerini C, Boschelli F, J Clin Oncol. 2009 Jan 20;27(3):469-71. - Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti- Passerini C, Int J Cancer. 2009 Apr 15;124(8):1990-6. - Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella- Deana A, Marin O, Perrotti D, Gambacorti-Passerini C, Blood. 2007 Oct 1;110(7):2600-9.

- Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza RG, Corneo G, Pogliani E, Nat Med. 2007 Jan;13(1):13-4. - Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza RG, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti- Passerini C, Cancer Res. 2006 Dec 1;66(23):11314-22. - Forlino A, Gualeni B, Pecora F, Torre SD, Piazza RG, Tiveron C, Tatangelo L, Superti- Furga A, Cetta G, Rossi A, Novartis Found Symp. 2006;273:193-206. - Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C, Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. - Franceschino A, Tornaghi L, Piazza R, Pogliani EM, Gambacorti-Passerini C, Haematologica. 2006 Jun;91(6 Suppl):ECR14. - Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C, Leukemia 2005 Nov;19(11):1985-7. - Forlino A*, Piazza RG*, Tiveron C, Della Torre S, Tatangelo L, Bonafe L, Gualeni B, Romano A, Pecora F, Superti-Furga A, Cetta G, Rossi A, (*Joint First Authors), Hum Mol Genet. 2005 Mar 15;14(6):859-71. - Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti- Passerini C, Leukemia. 2005 Jan;19(1):132-4. - Gambacorti-Passerini C, Piazza RG, Tornaghi L, Pilotti S, Pogliani E, Journal of the National Cancer Institute, Vol. 96, No. 22, November 17, 2004. - Gambacorti-Passerini C, Piazza RG, D'Incalci M, Blood. 2003 Sep 1;102(5):1933-4. - Gambacorti-Passerini C, Gunby R, Piazza RG, Galietta A, Rostagno R, Scapozza L, Lancet Oncology, 2003 Feb;4(2):75-85. - Rossi A, Cetta G, Piazza RG, Bonaventure J, Steinmann B, Superti-Furga A, Pediatric Pathology and Molecular Medicine, 2003 Jul-Aug;22(4):311-21. - Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza RG, Mallet JF, Delezoide AL, Munnich A, Bonaventure J, Zylberberg L, Journal of bone and mineral research, 2000 Aug;15(8):1489-500.